BLUESTAR GENOMICS INC. (ClearNote Health)

History

YearDetail
2016 Quake co-founded Bluestar Genomics to develop advanced liquid biopsy tests to address the deadliest cancers by detecting cancer signals earlier than existing methods.
2019 Bluestar Genomics presented new data demonstrating feasibility of a novel blood test for earlier detection and classification of multiple cancers.
2020 Bluestar Genomics and the University of Chicago collaboratively published the first complete genome map of key biomarkers for the detection of cancer and other diseases.
2022 At the American Pancreatic Association's annual meeting, the company launched a physician experience program to bring its pancreatic cancer detection test into clinical use based on positive validation study results reported.
  Bluestar Genomics Rebrands as ClearNote Health.
2023 ClearNote Health collaborated with Bayer to investigate Drug Treatment Response (DTR) by Liquid Biopsy in Prostate Cancer.
AI Sentiment